8-K: Senseonics Reports Q1 2025 Financial Results: Revenue Up 24% Driven by Eversense 365 Adoption

Senseonics Holdings, Inc. announced a 24% year-over-year increase in revenue for Q1 2025, driven by the adoption of its Eversense 365 continuous glucose monitoring (CGM) system and progress in strategic partnerships.

Summary

• Senseonics Holdings, Inc. reported its financial results for the first quarter ended March 31, 2025.
• Total revenue for Q1 2025 was $6.3 million, a 24% increase compared to $5.0 million in Q1 2024.
• U.S. revenue increased to $4.5 million from $3.7 million year-over-year, while revenue outside the U.S. rose to $1.8 million from $1.3 million.
• Gross profit for Q1 2025 was $1.5 million, compared to $0.3 million in Q1 2024, driven by improved margins on the Eversense 365 product.
• Selling, general, and administrative expenses decreased by $0.4 million year-over-year to $7.7 million.
• Research and development expenses decreased by $3.1 million year-over-year to $7.3 million due to the completion of 365-day product trials.
• Net loss decreased to $14.3 million, or $0.02 loss per share, from $18.9 million, or $0.03 loss per share, in Q1 2024.
• Senseonics expects full-year 2025 global net revenue to be approximately $34-38 million.
• Gross margins are expected to increase throughout 2025, with full-year gross margins between 25-30%.
• Cash used in operations in 2025 is expected to be between $50-$60 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to revenue growth, improved gross margins, and strategic partnerships. However, the continued net loss and cash burn temper the overall outlook.

Positives

• Revenue increased by 24% year-over-year in Q1 2025.
• Gross profit improved significantly due to higher margins on the Eversense 365 product.
• Operating expenses decreased due to lower personnel costs, consulting fees, legal expenses, and reduced R&D spending after the completion of 365-day product trials.
• Net loss decreased by $4.6 million compared to the same quarter last year.
• CMS reimbursement for Eversense 365 provides better access for Medicare beneficiaries.
• The partnership with Sequel to integrate with the twiist AID system enhances the product offering.
• The CE Mark application for Eversense 365 in Europe expands the market opportunity.

Negatives

• The company continues to operate at a net loss, with a loss of $14.3 million in Q1 2025.
• Cash used in operations is expected to be between $50-$60 million for the full year 2025.

Risks

• The company's financial outlook depends on the successful rollout of Eversense 365 and the doubling of the global patient base during 2025.
• The financial outlook is subject to assumptions regarding regulatory approval timelines, commercial transition outside the U.S., DTC marketing campaign spending, and the impact of patient assistance programs.
• Uncertainties exist regarding the reliance on Ascensia Diabetes Care as the commercialization partner.
• The company faces risks related to insurer, regulatory, and administrative processes and decisions.
• There are uncertainties inherent in the development and roll-out of new technology and solutions.

Future Outlook

Senseonics anticipates full-year 2025 global net revenue to be approximately $34-38 million, with gross margins between 25-30%. The company expects to double its global patient base during 2025, with revenue weighted towards the second half of the year.

Management Comments

• Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics, stated that the company continues to execute on its strategy to make Eversense easier to access and more flexible to use.
• He highlighted the positive CMS reimbursement as a major milestone and the collaboration with Sequel as an important step towards integrating CGM and insulin delivery technologies.

Industry Context

Senseonics is operating in the competitive continuous glucose monitoring (CGM) market. The partnership with Sequel to integrate with an automated insulin delivery (AID) system is a strategic move to enhance its product offering and compete with established players like Dexcom and Abbott. The CMS reimbursement update provides a significant advantage for Eversense 365 in the Medicare market.

Comparison to Industry Standards

• Dexcom and Abbott are the market leaders in the CGM space.
• Dexcom's G7 and Abbott's FreeStyle Libre 3 are the main competitors.
• Senseonics' Eversense differentiates itself with its long-term implantable sensor, offering up to 365 days of continuous monitoring, while Dexcom and Abbott's sensors typically last 10-14 days.
• The integration with Sequel's twiist AID system aims to provide a more comprehensive solution, similar to integrated systems offered by Medtronic and Tandem Diabetes Care.

Stakeholder Impact

• Shareholders will be impacted by the revenue growth and improved financial performance.
• Patients with diabetes will benefit from the expanded access and improved technology of Eversense 365.
• Employees may see increased job security and growth opportunities as the company expands.
• The partnership with Sequel benefits both companies and their respective stakeholders.

Next Steps

• Commercial launch of twiist with Eversense 365 is expected in Q3 2025.
• Launch of Eversense 365 in the European Union is expected in the second half of 2025.
• Continued rollout of Eversense 365 to U.S. patients.
• Focus on sales and marketing initiatives to drive adoption.
• Continued progress with the transition of reimbursement from Eversense E3 to Eversense 365.

Key Dates

Keywords

Senseonics, Eversense 365, Continuous Glucose Monitoring, CGM, Diabetes, Financial Results, Revenue, Gross Profit, Sequel, twiist AID, CMS Reimbursement, CE Mark, SweetSpot